PRMT5-Mediated Methylation of NF-κB p65 at Arg174 Is Required for Endothelial CXCL11 Gene Induction in Response to TNF-α and IFN-γ Costimulation

Inflammatory agonists differentially activate gene expression of the chemokine family of proteins in endothelial cells (EC). TNF is a weak inducer of the chemokine CXCL11, while TNF and IFN-gamma costimulation results in potent CXCL11 induction. The molecular mechanisms underlying TNF plus IFN-gamma-mediated CXCL11 induction are not fully understood. We have previously reported that the protein arginine methyltransferase PRMT5 catalyzes symmetrical dimethylation of the NF-kappa B subunit p65 in EC at multiple arginine residues. Methylation of Arg(30) and ArWg(35) on p65 is critical for TNF induction of CXCL10 in EC. Here we show that PRMT5-mediated methylation of p65 at Arg(174) is required for induction of CXCL11 when EC are costimulated with TNF and IFN-gamma. Knockdown of PRMT5 by RNAi reduced CXCL11 mRNA and protein levels in costimulated cells. Reconstitution of p65 Arg(174)Ala or Arg(174)Lys mutants into EC that were depleted of endogenous p65 blunted TNF plus IFN-gamma mediated CXCL11 induction. Mass spectrometric analyses showed that p65 Arg(174) arginine methylation is enhanced by TNF plus IFN-gamma costimulation, and is catalyzed by PRMT5. Chromatin immunoprecipitation assays (ChIP) demonstrated that PRMT5 is necessary for p65 association with the CXCL11 promoter in response to TNF plus IFN-gamma. Further, reconstitution of p65 Arg(174)Lys mutant in EC abrogated this p65 association with the CXCL11 promoter. Finally, ChIP and Re-ChIP assays revealed that symmetrical dimethylarginine-containing proteins complexed with the CXCL11 promoter were diminished in p65 Arg(174)Lys-reconstituted EC stimulated with TNF and IFN-gamma. In total, these results indicate that PRMT5-mediated p65 methylation at Arg(174) is essential for TNF plus IFN-gamma-mediated CXCL11 gene induction. We therefore suggest that the use of recently developed small molecule inhibitors of PRMT5 may present a therapeutic approach to moderating chronic inflammatory pathologies.